CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics (PSTV), announced that it has signed a national agreement with UnitedHealthcare Insurance Company (UNH), effective September 15, 2025, to provide the CNSide Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test, LDT. The CNSide CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The clinical utility of CNSide over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics announces $1.9M advance payment from CPRIT
- Plus Therapeutics announces accreditation, certification for CNSide Diagnostics
- Plus Therapeutics upgraded to Buy from Hold at D. Boral Capital
- Plus Therapeutics regains compliance with applicable Nasdaq listing criteria
- Plus Therapeutics Secures Nasdaq Compliance Extension